Non-compliance: the Achilles' heel of anti-fracture efficacy

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Osteoporosis International

• Publication date

  2007-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-006-0294-8PMID 17245547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Alendronate (Fosamax®) for the Treatment of Osteoporosis and Prevention of Fractures

  2012cited by this paper
• Persistence with weekly alendronate therapy among postmenopausal women

  2006influential reference
• Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study

  2006cited by this paper
• Assessment of compliance with osteoporosis treatment and its consequences in a managed care population.

  2006cited by this paper
• Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model

  2006cited by this paper
• Calcium plus vitamin D for postmenopausal women--bone appétit?

  2006cited by this paper
• The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

  2006cited by this paper
• An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting

  2006cited by this paper
• Calcium plus vitamin D supplementation and the risk of fractures.

  2006cited by this paper
• Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

  2006cited by this paper
• Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy.

  2005influential reference
• Treatment of Postmenopausal Osteoporosis

  2005cited by this paper
• A model of osteoporosis impact in Switzerland 2000–2020

  2005influential reference
• Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature

  2005cited by this paper
• Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study

  2005cited by this paper
• Using data from automated dispensing units to identify adverse drug reactions.

  2005cited by this paper
• Compliance with osteoporosis medications.

  2005influential reference
• In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.

  2005cited by this paper
• Costs and quality of life associated with osteoporosis-related fractures in Sweden

  2005cited by this paper
• Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study

  2005cited by this paper
• Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral density.

  2005cited by this paper
• Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis*

  2005cited by this paper
• Incidence and causes for failure of treatment of women with proven osteoporosis

  2005cited by this paper
• Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark

  2005cited by this paper
• Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women.

  2005cited by this paper
• Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

  2005cited by this paper
• Osteoporosis: underrated, underdiagnosed and undertreated

  2004cited by this paper
• Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

  2004cited by this paper
• The impact of compliance with osteoporosis therapy on fracture rates in actual practice

  2004cited by this paper
• A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture

  2004cited by this paper
• The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

  2004cited by this paper
• Compliance with drug therapies for the treatment and prevention of osteoporosis.

  2004cited by this paper
• Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis.

  2004cited by this paper
• Multicultural medication adherence: a comparative study.

  2004cited by this paper
• Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.

  2004cited by this paper
• Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study

  2004cited by this paper
• Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics.

  2004cited by this paper
• Compliance of osteoporotic patients with different treatment regimens.

  2003cited by this paper
• Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment.

  2003cited by this paper
• Relationship Between Changes in Bone Mineral Density and Fracture Risk Reduction With Antiresorptive Drugs: Some Issues With Meta‐Analyses

  2003cited by this paper
• Compliance with pharmacologic therapy for osteoporosis

  2003cited by this paper
• Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database

  2003cited by this paper
• Reliability and Validity of the Self-Efficacy and Outcome Expectations for Osteoporosis Medication Adherence Scales

  2003cited by this paper
• Treatment of postmenopausal osteoporosis.

  2002cited by this paper
• Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis

  2002cited by this paper
• Long-Term Risk of Osteoporotic Fracture in Malmö

  2000cited by this paper
• Determinants of long-term hormone replacement therapy and reasons for early discontinuation.

  2000cited by this paper
• Effect of age on reasons for initiation and discontinuation of hormone replacement therapy.

  1999cited by this paper
• Practical HRT, Ed. 2

  1999cited by this paper
• Estimating the Costs of Hip Fracture and Potential Savings

  1998cited by this paper
• Improving compliance with hormonal replacement therapy in primary osteoporosis prevention.

  1997cited by this paper
• The cost of a hip fracture. Estimates for 1,709 patients in Sweden.

  1997cited by this paper
• The assessment of refill compliance using pharmacy records: methods, validity, and applications.

  1997influential reference
• Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis

  1992cited by this paper
• Patient Compliance in Medical Practice and Clinical Trials

  1991cited by this paper
• Treatment adherence and risk of death after a myocardial infarction.

  1990cited by this paper
• An assessment of clinically useful measures of the consequences of treatment.

  1988cited by this paper
• Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project.

  1980cited by this paper
• Sociobehavioral Determinants of Compliance with Health and Medical Care Recommendations

  1975cited by this paper

• Prune consumption attenuates pro-inflammatory cytokine secretion and alters monocyte activation in postmenopausal women: secondary outcome analysis of a 12-month randomized controlled trial: The Prune Study.

  2023cites this paper
• Investigating the impact of a national educational program on patient adherence to osteoporosis medications

  2023cites this paper
• Physician-Reported Barriers to Osteoporosis Screening: A Nationwide Survey.

  2023cites this paper
• Difficulties in decision making on a long standing, complicated case of osteoporosis – a real challenge for functional rehabilitation

  2023cites this paper
• Validation and optimization of the French Generic Adherence for Chronic Diseases Profile (GACID-P) using classical test and item response theory

  2023cites this paper
• Osteoporosis Management: Gaps in Patients’ Care and Treatment

  2022cites this paper
• Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance

  2022cites this paper
• Osteoporosis Update for Primary Care Physicians

  2022cites this paper
• Health and Quality of Life Outcomes

  2022cites this paper
• Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms

  2022cites this paper
• Pitfalls in DXA Scanning

  2022cites this paper
• Fracture Liaison Service (FLS) for secondary prevention of fragility fractures: the Italian IMPACT Project

  2022cites this paper
• Effectiveness of bisphosphonates on bone mineral density in osteopenic postmenopausal women

  2021cites this paper
• Management of osteoporosis in women with breast cancer

  2020cites this paper
• Low acceptance of osteoanabolic therapy with parathyroid hormone in patients with fragility fracture of the pelvis in routine clinical practice: a retrospective observational cohort study

  2019cites this paper
• Use of antiosteoporotic medication in the Danish ROSE population-based screening study

  2019cites this paper
• Factors associated with discontinuation of antidepressant treatment after a single prescription among patients aged 55 or over: evidence from English primary care

  2019cites this paper
• (2019). Factors associated with discontinuation of antidepressant treatment after a single prescription among patients aged 55 or over: evidence from English primary care. Social Psychiatry and Psychiatric Epidemiology,

  2019cites this paper
• Wenn die Knochen schwinden

  2019cites this paper
• Persistance et tolérance du tériparatide dans l’ostéoporose : résultats d’une étude observationnelle dite de « vraie vie »

  2019cites this paper
• Bisphosphonates for Postmenopausal Osteoporosis

  2018cites this paper
• Eine regionale Analyse der Tertiärprävention

  2018cites this paper
• Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study

  2018cites this paper
• Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice.

  2018cites this paper
• A concept analysis of deprescribing medications in older people

  2018cites this paper
• Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

  2017cites this paper
• Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology

  2017cites this paper
• Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

  2017cites this paper
• Draft Recommendations. Pharmacotherapy for the Prevention of Repeated Fractures in Patients with Osteoporosis after Surgical Treatment of Pathologic Proximal Femur Fracture

  2017cites this paper
• Knowledge on Osteoporosis among Nurses

  2017cites this paper
• Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion.

  2017cites this paper
• Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24‐month Clinical Study

  2017cites this paper
• Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States

  2016cites this paper
• RETRACTED ARTICLE: Cost-effectiveness of dual energy X-ray absorptiometry (DXA) plus anti-resorptive treatment in Australian women with breast cancer who receive aromatase inhibitors

  2016cites this paper
• Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday

  2016cites this paper
• Correlation between zoledronic acid infusion and repeat vertebroplasty surgery in osteoporotic patients

  2016cites this paper
• Real-world clinical and economic outcomes for daily teriparatide patients in Japan

  2016cites this paper
• Lyndra White Paper on Adherence to Medication 2016-09-24

  2016cites this paper
• Fracture Liaison Services

  2016cites this paper
• Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study

  2015cites this paper
• Encounter Decision Aid vs. Clinical Decision Support or Usual Care to Support Patient-Centered Treatment Decisions in Osteoporosis: The Osteoporosis Choice Randomized Trial II

  2015cites this paper
• Enhancement of hip fracture healing in the elderly: Evidence deriving from a pilot randomized trial.

  2015cites this paper
• Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter

  2015cites this paper
• Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study

  2015cites this paper
• Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic

  2015cites this paper
• Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.

  2015cites this paper
• Anti-osteoporosis therapy and fracture healing

  2014cites this paper
• Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries

  2014cites this paper
• The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report

  2014cites this paper
• Osteoporosis: The Need for Prevention and Treatment

  2014cites this paper
• Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.

  2014cites this paper
• The Intersection of Plant Breeding, Human Health, and Nutritional Security: Lessons Learned and Future Perspectives

  2014cites this paper
• Knowledge on Osteoporosis of Prescriber According to Level of Medical Institute

  2014cites this paper
• Consumption of osteoanabolic drugs and strontium ranelate in the treatment of osteoporosis in the Czech Republic in 2005-2011.

  2014cites this paper
• Monitoring osteoporosis therapy: Can FRAX help assessing success or failure in achieving treatment goals?

  2014cites this paper
• Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider

  2014influential citation
• Life with osteoporosis: a cohort and qualitative studyen kohorte og kvalitativ undersøgelse

  2014cites this paper
• Residual effect after oral bisphosphonate treatment and healthy adherer effects—the Swedish adherence register analysis (SARA)

  2014cites this paper
• Safety concerns with the long-term management of osteoporosis

  2013cites this paper
• Bisphosphonate use and subsequent hip fracture in South Korea

  2013cites this paper
• Incidence of second hip fracture and compliant use of bisphosphonate

  2013cites this paper
• Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference

  2013cites this paper
• Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study

  2013cites this paper
• Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

  2013cites this paper
• Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases

  2013cites this paper
• The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis

  2013cites this paper
• Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm

  2013cites this paper
• Adherence to anti-osteoporotic therapies: role and determinants of “spot therapy”

  2013cites this paper
• Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study.

  2013cites this paper
• The savings factor between treatment of osteoporosis and treatment of subsequent osteoporotic fracture in the Netherlands.

  2013cites this paper
• Secondary prevention and estimation of fracture risk.

  2013cites this paper
• Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database

  2012cites this paper
• Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.

  2012cites this paper
• Improving patients’ outcomes after osteoporotic fractures

  2012cites this paper
• Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors

  2012cites this paper
• A Review of the 2008 Singapore Ministry of Health Clinical Practice Guidelines on Osteoporosis and an Update

  2012cites this paper
• The impact of teriparatide adherence and persistence on fracture outcomes

  2012cites this paper
• Persistence with intravenous zoledronate in elderly patients with osteoporosis

  2012cites this paper
• Economic burden of osteoporotic fractures in Austria

  2012cites this paper
• What can be done to maximize adherence of bisphosphonates in patients with osteoporosis

  2012cites this paper
• Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.

  2011cites this paper
• Adherence to osteoporosis treatment with once-monthly bisphosphonate

  2011cites this paper
• Malic enzyme gene polymorphism is associated with responsiveness in circulating parathyroid hormone after long-term calcium supplementation

  2011cites this paper
• The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands

  2011cites this paper
• When do bisphosphonates make the most sense?

  2011cites this paper
• [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].

  2011influential citation
• New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis—CEE”, November 2009, Budapest, Hungary

  2011cites this paper
• Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

  2011cites this paper
• Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

  2011influential citation
• Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance

  2011influential citation
• The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

  2010cites this paper
• Risk communication and shared decision making in the care of patients with osteoporosis.

  2010cites this paper
• Original article Peripatetic intravenous service for metabolic bone disease: case study in patient centred-care for new NHS

  2010cites this paper
• Adherence, Compliance, and Persistence with Osteoporosis Therapies

  2010cites this paper
• Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications

  2010cites this paper
• PRIVERZhENNOST' K LEChENIYu OSTEOPOROZA: VOPROSPERENOSIMOSTI, REZhIMA LEChENIYaILI ISKLYuChITEL'NO KhOROShEGO DIALOGA S PATsIENTOM?

  2010cites this paper
• Peripatetic intravenous service for metabolic bone disease: case study in patient centred-care for new NHS

  2010cites this paper
• Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

  2010cites this paper
• Zoledronic acid infusion for prevention and treatment of osteoporosis

  2010cites this paper
• The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

  2010cites this paper